An attempt to conceptualize the individual onco-functional balance: Why a standardized treatment is an illusion for diffuse low-grade glioma patients

https://doi.org/10.1016/j.critrevonc.2017.12.008Get rights and content

Abstract

In the era of evidence-based medicine, clinicians aim to establish standards of care from randomized studies. Following, personalized medicine has emerged, as new individualized biomarkers could help to predict sensitivity to specific treatment.

In this paper, we show that, for diffuse low-grade glioma, some specificities – dual goal of both survival and functional gain, long duration of the disease with multistep treatments, multiparametric evaluation of the onco-functional balance of each treatment modality – call for a change of paradigm. After summarizing how to weight the benefits and risks of surgery, chemotherapy and radiotherapy, we show that the overall efficacy of a treatment modality cannot be assessed per se, as it depends on its integration in the whole sequence. Then, we revisit the notion of personalized medicine: instead of decision-making based solely on molecular profile, we plead for a recursive algorithm, allowing a dynamic evaluation of the onco-functional balance, integrating many individual characteristics of the patient’s tumor and brain function.

Introduction

Diffuse low-grade glioma (DLGG) constitutes a particular case of cancer, characterized by an initial period of slow growth in a patient without any neurological deficits. At some point, malignant transformation towards a higher grade occurs, leading to neurological impairment and ultimately to death. Our current inability to cure these tumors likely stems from their genetic, epigenetic and phenotypic plasticity and from our poor understanding of their true etiology (Darlix et al., 2017). Thanks to advances over the last two decades in the multistep sequence combining surgery, chemotherapy (CT), and radiation therapy (RT), survival rates greatly improved, with median survivals now greater than 10 years in most recent studies (Buckner et al., 2016, Capelle et al., 2013, Jakola et al., 2012, Roelz et al., 2016, Smith et al., 2008). This means that, if ones aims to improve not only survival but also time with quality of life (Mandonnet et al., 2012), the selection of a treatment at any time in the sequence should weight its oncological interest (positive effect on survival) against its expected short- and long-term functional consequences. In other words, the choice of a treatment at a given time consists in optimizing the so called onco-functional balance (Duffau and Mandonnet, 2013).

At the first level, we propose to review our current knowledge enabling to evaluate the oncological benefit and the functional risk of each treatment type, independently of its integration in the sequence. But because one also wants to compare the onco-functional balance of each treatment modality in reference to the natural history, this first level analysis will be preceded by a short recall of some essential elements of the natural history of DLGG, both on an oncological and functional perspective.

At the second level, the same balance has to be reevaluated in the framework of a multistep sequential approach. Indeed, the overall efficacy of a treatment cannot be assessed per se, as we will show that it will be highly dependent on its integration in the whole sequence. For example, the same response to temozolomide will have a different oncological impact whether it is complemented (hopefully synergistically) or not by a surgery or a radiation therapy. Hence, in order to select the best treatment at each step, one should also have in mind both the previous and the next steps.

At the third level, the two previous levels have to be reevaluated at the individual scale, based on personalized parameters, characterizing both the tumor and the brain functioning of the patient. In other words, the timing and order of the sequence steps have to be fitted to each patient, taken into consideration both tumor and functional individual characteristics, and their interactions. For example, the very same extent of resection has a different value in a slow growing tumor (allowing a repeat surgery after a couple of years of full cognitive recovery) or in a fast growing tumor (requiring in the next step a chemotherapy or a radiation therapy because of a low plasticity reserve resulting from the fast growth).

Finally, we propose a recursive algorithm that can assist clinicians in the complex task of finding the optimal personalized treatment sequence for each patient.

Section snippets

Elements of natural history of DLGG and its interaction with the brain

From an oncological point of view, DLGG can be considered as premalignant lesions. Indeed, these lesions are at risk of malignant transformation, with both functional and life-threatening consequences. During the low-grade period, the tumor growth is continuous and slow (about 4 mm/year on average (Mandonnet et al., 2003)). The risk of malignant transformation increases with tumor volume and with tumor growth rates. Hence, from an oncological point of view, treatments goal is to reduce both

Short-term oncological benefit: removal of a « hot » spot

It is now well recognized that DLGG might exhibit spatial heterogeneities. New imaging techniques enable to detect such heterogeneities. In particular, dynamic 18F FET-PET allows to identify foci of decreasing time-activity curves, that correlate with histological grade (Thon et al., 2015). Similarly, the role of perfusion imaging to detect such hot spots is still investigated. Although this has not yet been proven, it can be anticipated that removal of such malignant foci within an otherwise

Second level onco-functional balance: integrating each treatment in the whole sequence

Beyond the onco-functional balance intrinsically related to a given treatment, the choice of a treatment modality should be reevaluated in light of its interaction with associated treatments in the whole sequence. In this part, we propose to review some of these interactions.

Importance of patient’s way of life and wishes in surgical planning

Since postoperative cognitive evaluations are performed on a routine basis, our knowledge of the impact of surgery on high-level functions has greatly improved, leading to a better preoperative personalized estimation of functional risk. To this end, the importance of the preoperative patient interview cannot be overemphasized. Patient should clearly formulate his wishes regarding which kind of functions should be primarily preserved. This will depend on its way of life, including profession,

Proposal of a recursive algorithm of multistep treatment in DLGG patients

In light of our current knowledge, we suggest that DLGG patients would benefit from a recursive reasoning, as explicited in Fig. 2. Whenever possible, maximal resection tailored on functional boundaries for preserving functions preoperatively defined with the patient remains the treatment of first intention (Soffietti et al., 2010). Judging for functional operability constitutes presently a subjective expertise based on surgeon’s experience. However, new methodological tools are under

Conclusion

Implementing an optimal sequential multistep strategy in DLGG patients is quite complex: we have shown that, beyond the role of each individual treatment, second order effects can potentiate the effect of each individual treatment. The proposed recursive design can serve as a guide, in keeping with the fundamental principle that the onco-functional balance of each treatment modality has to be updated all along the evolution. In this perspective, future randomized trial in DLGG should evaluate

Conflict of interest

none.

Funding statement

none.

References (90)

  • T. Mazor et al.

    DNA methylation and somatic mutations converge on the cell cycle and define similar evolutionary histories in brain tumors

    Cancer Cell

    (2015)
  • K.R. Swanson et al.

    Virtual resection of gliomas: effect of extent of resection on recurrence

    Math Comput. Model

    (2003)
  • M.J. van den Bent et al.

    EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial

    Lancet

    (2005)
  • Y.Z. Al-Tamimi et al.

    Low-grade glioma with foci of early transformation does not necessarily require adjuvant therapy following radical surgical resection

    World Neurosurg.

    (2017)
  • F. Almairac et al.

    The left inferior fronto-occipital fasciculus subserves language semantics: a multilevel lesion study

    Brain Struct. Funct.

    (2015)
  • H. Bai et al.

    Integrated genomic characterization of IDH1-mutant glioma malignant progression

    Nat. Genet.

    (2016)
  • M.S. Berger et al.

    The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas

    Cancer

    (1994)
  • M. Blonski et al.

    Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life

    J. Neurooncol.

    (2012)
  • M. Blonski et al.

    Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients

    J. Neurooncol.

    (2013)
  • J. Boetto et al.

    Low rate of intraoperative seizures during awake craniotomy in a prospective cohort with 374 supratentorial brain lesions: electrocorticography is not mandatory

    World Neurosurg.

    (2015)
  • J.C. Buckner et al.

    Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma

    N. Engl. J. Med.

    (2016)
  • G. Cairncross et al.

    Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402

    J. Clin. Oncol.

    (2013)
  • F. Campanella et al.

    Long-term cognitive functioning and psychological well-being in surgically treated patients with low-grade glioma

    World Neurosurg.

    (2017)
  • L. Capelle et al.

    Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article

    J. Neurosurg.

    (2013)
  • J. Cochereau et al.

    Patients with incidental WHO grade II glioma frequently suffer from neuropsychological disturbances

    Acta Neurochir. (Wien)

    (2016)
  • E.J. Curran

    A new association fiber tract in the cerebrum

    J. Comp. Neurol. Psychol. XIX

    (1909)
  • P.C. De Witt Hamer et al.

    Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis

    J. Clin. Oncol.

    (2012)
  • P.C. De Witt Hamer et al.

    Resection probability maps for quality assessment of glioma surgery without brain location bias

    PLoS One

    (2013)
  • M. Desmurget et al.

    Contrasting acute and slow-growing lesions: a new door to brain plasticity

    Brain

    (2007)
  • H. Duffau et al.

    The onco-functional balance in surgery for diffuse low-grade glioma: integrating the extent of resection with quality of life

    Acta Neurochir. (Wien)

    (2013)
  • H. Duffau et al.

    Radical surgery after chemotherapy: a new therapeutic strategy to envision in grade II glioma

    J. Neurooncol.

    (2006)
  • H. Duffau

    Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up

    Acta Neurochir. (Wien)

    (2016)
  • H. Duffau
  • F. Ghareeb et al.

    Intractable epilepsy in paralimbic Word Health Organization Grade II gliomas: should the hippocampus be resected when not invaded by the tumor?

    J. Neurosurg.

    (2012)
  • C.D. Ghinda et al.

    Network plasticity and intraoperative mapping for personalized multimodal management of diffuse low-grade gliomas

    Front. Surg.

    (2017)
  • G. Herbet et al.

    Inferring a dual-stream model of mentalizing from associative white matter fibres disconnection

    Brain

    (2014)
  • G. Herbet et al.

    Interfering with the neural activity of mirror-related frontal areas impairs mentalistic inferences

    Brain Struct. Funct.

    (2015)
  • G. Herbet et al.

    Mapping neuroplastic potential in brain-damaged patients

    Brain

    (2016)
  • G. Herbet et al.

    Converging evidence for a cortico-subcortical network mediating lexical retrieval

    Brain

    (2016)
  • C. Izquierdo et al.

    Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics

    J. Neurooncol.

    (2017)
  • A.S. Jakola et al.

    Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas

    JAMA

    (2012)
  • S. Jbabdi et al.

    Simulation of anisotropic growth of low-grade gliomas using diffusion tensor imaging

    Magn. Reson. Med.

    (2005)
  • J. Jo et al.

    Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma

    J. Neurooncol.

    (2014)
  • B.E. Johnson et al.

    Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma

    Science

    (2014)
  • G. Kaloshi et al.

    Kinetic evaluation of low-grade gliomas in adults before and after treatment with CCNU alone

    J. Neurosurg.

    (2015)
  • Cited by (55)

    • Present bias in economic choice demonstrates increased cognitive fatigability of glioma patients

      2022, Cortex
      Citation Excerpt :

      Whenever feasible, maximal safe resection is the first treatment option (Weller et al., 2017). Timing and choice of subsequent therapies (reoperation, chemotherapy, radiation therapy, combined chemoradiotherapy) should then be tailored according to multivariate individual parameters (Mandonnet & Duffau, 2018). More specifically, the decision should rely on a comparison of the benefit (increased survival) – risk (functional impairment) ratio between available options.

    View all citing articles on Scopus
    View full text